To access the full text documents, please follow this link: http://hdl.handle.net/2445/144621
dc.contributor.author | Liapikou, Adamantia |
---|---|
dc.contributor.author | Cillóniz, Catia |
dc.contributor.author | Mensa Pueyo, Josep |
dc.contributor.author | Torres Martí, Antoni |
dc.date | 2019-11-12T15:10:00Z |
dc.date | 2019-11-12T15:10:00Z |
dc.date | 2014-05-27 |
dc.date | 2019-11-12T15:10:00Z |
dc.identifier | 1094-5539 |
dc.identifier | 645173 |
dc.identifier | 2662834 |
dc.identifier | 24878422 |
dc.identifier.uri | http://hdl.handle.net/2445/144621 |
dc.description | Nowadays, we face growing resistance among gram-positive and gram-negative pathogens that cause respiratory infection in the hospital and in the community. The spread of penicillin- and macrolide-resistant pneumococci, Community-acquired methicillin-resistant staphylococcus aureus (Ca-MRSA), the emergence of glycopeptide-resistant staphylococci underline the need for underline the need for therapeutic alternatives. A number of new therapeutic agents, with activity against the above Gram (+) respiratory pathogens, as ceftaroline, ceftopibrole, telavancin, tedizolid have become available, either in clinical trials or have been approved for clinical use. Especially, the development of new oral antibiotics, as nemonaxacin, omadacyclin, cethromycin and solithromycin will give a solution to the lack of oral drugs for outpatient treatment. In the future the clinician needs to optimize the use of old and new antibiotics to treat gram (+) respiratory serious infections. |
dc.format | 131 p. |
dc.format | application/pdf |
dc.language | eng |
dc.publisher | Elsevier |
dc.relation | Versió postprint del document publicat a: https://doi.org/10.1016/j.pupt.2014.05.003 |
dc.relation | Pulmonary Pharmacology and Therapeutics, 2014, vol. 32, p. 13-143 |
dc.relation | https://doi.org/10.1016/j.pupt.2014.05.003 |
dc.rights | (c) Elsevier, 2014 |
dc.rights | info:eu-repo/semantics/openAccess |
dc.subject | Infeccions respiratòries |
dc.subject | Infeccions per pneumococs |
dc.subject | Respiratory infections |
dc.subject | Pneumococcal Infections |
dc.title | New antimicrobial approaches to gram positive respiratory infections |
dc.type | info:eu-repo/semantics/article |
dc.type | info:eu-repo/semantics/acceptedVersion |